Executive leadership at Kairos Pharma.
Board of directors at Kairos Pharma.
Research analysts covering Kairos Pharma.
Recent press releases and 8-K filings for KAPA.
Kairos Pharma to Present Positive Phase 2 Prostate Cancer Data at ESMO 2025 and Assumes Key Licenses
KAPA
New Projects/Investments
- On October 1, 2025, Kairos Pharma, Ltd. (Kairos) entered into a novation agreement with Cedars-Sinai Medical Center to transfer the exclusive license of two patents from its wholly-owned subsidiary, Enviro Therapeutics, Inc., to Kairos, effective April 17, 2025.
- Kairos also assumed rights and obligations for TRC105 and CD105 technologies from Tracon Pharmaceuticals, Inc., previously held by Enviro, through a novation agreement effective September 24, 2025.
- Kairos announced on October 7, 2025, that it will present "Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer" at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, from October 17–21, 2025.
- The presentation will highlight interim analysis results from a Phase 2 trial evaluating ENV105 (carotuximab), a first-in-class CD105 antagonist, in 100 men with metastatic castration-resistant prostate cancer (mCRPC), demonstrating encouraging safety and early efficacy findings.
Oct 7, 2025, 12:00 PM
Kairos Pharma Announces Positive Interim Efficacy Data for ENV105 in Prostate Cancer Trial
KAPA
New Projects/Investments
- Kairos Pharma, Ltd. (KAPA) announced positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) for metastatic castration-resistant prostate cancer (mCRPC) on September 18, 2025.
- The interim analysis of 8 patients demonstrated a median progression-free survival of more than 13 months for ENV105 in combination with apalutamide, significantly exceeding the 3.7 months median efficacy of standard of care hormone therapy.
- Seven of nine patients in the interim analysis showed a decrease in their prostate-specific antigen (PSA) from baseline.
- An earlier interim safety analysis in July 2025 indicated that ENV105 was well tolerated, with no dose-limiting toxicities or unexpected adverse events reported.
Sep 18, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more